预约演示

更新于：2025-06-12

Rituximab

利妥昔单抗

更新于：2025-06-12

概要

基本信息

药物类型

单克隆抗体

别名

IDEC-C2B8-anti-CD20、Ristova、Rituximab (Genetical Recombination)

+ [14]

靶点

CD20

作用方式

抑制剂

作用机制

CD20抑制剂(B淋巴细胞抗原CD20抑制剂)、ADCC(抗体依赖的细胞毒作用)、CD20定向的溶细胞作用

治疗领域

肿瘤免疫系统疾病感染+ [11]

在研适应症

心脏移植排斥反应肝移植排斥反应肺移植排斥反应+ [143]

非在研适应症

急性双系白血病急性移植物抗宿主病成人急性髓性白血病+ [142]

原研机构

Genentech, Inc.

在研机构

Roche Holding AGGenmab, Inc.

Pharmacyclics LLC.

+ [42]

非在研机构

Jonsson Comprehensive Cancer CenterThe Sidney Kimmel Comprehensive Cancer Center

Fred Hutchinson Cancer Research Center

+ [41]

权益机构

上海罗氏制药有限公司

青岛百洋医药股份有限公司

Biogen, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (1997-11-26),

非霍奇金淋巴瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)

登录后查看时间轴

结构/序列

Sequence Code 27145L

来源: *****

Sequence Code 83181H

来源: *****

关联

2,520

项与利妥昔单抗相关的临床试验

NCT07015242

/ Not yet recruiting临床2期

The CAROLYN Trial: Lisocabtagene Maraleucelas First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

开始日期2025-09-30

申办/合作机构

Juno Therapeutics, Inc.

NCT06965114

/ Not yet recruiting临床1/2期IIT

A Phase 1b Study of Combination Tovorafenib (DAY101) and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib (DAY101) and Rituximab With Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia

This phase Ib/II trial tests the safety, side effects, and effectiveness of tovorafenib in combination with rituximab in patients with classical hairy cell leukemia (cHCL) that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory) and compares the effect of tovorafenib and rituximab to current standard treatment of cladribine and rituximab in cHCL patients that have not yet received treatment. Tovorafenib blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cladribine damages the cell's deoxyribonucleic acid and may kill cancer cells. It is a type of antimetabolite. Giving tovorafenib in combination with rituximab may be safe and tolerable and more effective than cladribine with rituximab in treating patients with untreated, recurrent or refractory cHCL.

开始日期2025-09-30

申办/合作机构

National Cancer Institute

NCT06918431

/ Not yet recruiting临床2期IIT

A Phase 2 Study Evaluating the Safety and Efficacy of Asparaginase Erwinia Chrysanthemi- Recombinant-Rywn (Recombinant Erwinia Asparaginase) During Pediatric-Inspired Regimen in High-Risk Adults With Newly Diagnosed ALL or LBL

This phase II trial tests the safety, side effects, and effectiveness of asparaginase Erwinia chrysanthemi during induction chemotherapy followed by consolidation chemotherapy in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. Asparaginase Erwinia chrysanthemi, a type of protein synthesis inhibitor, is a drug that is made up of the enzyme asparaginase, which comes from the bacterium Erwinia chrysanthemi, and is used with other drugs in people who cannot take asparaginase that comes from the bacterium E. coli. Asparaginase Erwinia chrysanthemi breaks down the amino acid asparagine and may stop the growth of cancer cells that need asparagine to grow. It may also kill cancer cells. Induction therapy, consisting of cytarabine, dexamethasone, vincristine, daunorubicin, methotrexate, and rituximab, is the first choice of treatment. Consolidation therapy, consisting of cyclophosphamide, cytarabine, vincristine, mercaptopurine, methotrexate and rituximab, is given after initial therapy to kill any remaining cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Cytarabine and mercaptopurine stop cells from making DNA and may kill cancer cells. They are a type of antimetabolite. Daunorubicin blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. It is a type of anthracycline antibiotic and a type of topoisomerase inhibitor. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving asparaginase Erwinia chrysanthemi with induction chemotherapy followed by consolidation chemotherapy may be safe, tolerable, and/or effective in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma.

开始日期2025-09-26

申办/合作机构

City of Hope National Medical Center

[+1]

100 项与利妥昔单抗相关的临床结果

登录后查看更多信息

100 项与利妥昔单抗相关的转化医学

登录后查看更多信息

100 项与利妥昔单抗相关的专利（医药）

登录后查看更多信息

27,902

项与利妥昔单抗相关的文献（医药）

2025-12-31·Future Science OA

Diagnosing pulmonary MALT lymphoma: a case of unilateral cystic lesions

Article

作者: Liao, Wenjian ; Qin, Yan ; Xiang, Tianxin ; Huang, Zhisheng ; Li, Ping

We present an atypical case of a 62-year-old female diagnosed with pulmonary mucosa-associated lymphoid tissue (p-MALT) lymphoma, which uniquely manifested as a singular cystic lesion in the lung. Diagnostic evaluations, including comprehensive imaging, bronchoscopy, and CT-guided lung biopsy, revealed this uncommon radiological presentation. Detailed histopathological and immunohistochemical assessments further supported the diagnosis. To determine the extent of the disease, systemic evaluations, such as whole-body PET-CT, gastroscopy, colonoscopy, and bone marrow biopsy, were conducted, confirming its localized nature. Following the definitive diagnosis, the patient underwent a rituximab-centric therapeutic regimen, which yielded significant clinical improvement. This case highlights the importance of recognizing distinctive cystic lung features in p-MALT lymphoma and the indispensable role of holistic diagnostic approaches in guiding precise therapeutic and prognostic decisions.

2025-12-31·Hematology

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports

Article

作者: Ghanima, Waleed ; Rackwitz, Stefan ; Lucas Boronat, Francisco Javier ; Carrai, Valentina

INTRODUCTION:

A goal of most primary immune thrombocytopenia (ITP) treatments is reducing or discontinuing treatment while maintaining a response including an absence of bleeding events. We present four cases describing treatment with the spleen tyrosine kinase (SYK) inhibitor, fostamatinib, that showed sustained response off treatment (SROT).

CASE PRESENTATIONS:

Case 1 was a 66-year-old male with chronic ITP. He was pre-treated with prednisone and rituximab before being in the FIT-2 clinical trial (placebo). He received fostamatinib in the FIT-3 open-label extension for seven weeks and maintained SROT for 2.5 years. Case 2 was a 54-year-old female patient with chronic, highly refractory ITP. SROT was achieved after 6 months of fostamatinib and was maintained for more than 16 months (in remission to date). Case 3 was a 60-year-old male with chronic ITP. He was successfully treated with cycles of corticosteroids for six years prior to fostamatinib. He was treated with fostamatinib plus prednisone for approximately two months. SROT was observed in this patient for one year. Case 4 was a 67-year-old male with persistent ITP. Before fostamatinib, he was unresponsive to high-dose dexamethasone, IVIG, eltrombopag and romiplostim. After 11 months of fostamatinib, his dose was tapered for three months and ultimately discontinued. SROT was observed for more than ten months (in remission to date).

DISCUSSION:

These cases emphasize that SROT is achievable with fostamatinib in complex ITP cases unresponsive to multiple previous therapies. Additional research is needed to identify the magnitude of the underlying mechanisms, and the clinical factors associated with, and potentially predictive of, SROT.

2025-12-31·RENAL FAILURE

The efficacy and safety of rituximab monotherapy in the new onset pediatric idiopathic nephrotic syndrome: a randomized controlled clinical trial

Article

作者: He, Si-Yi ; Zhao, Jing-Li ; Dou, Ya-Lan ; Wang, Jing-Jing ; Shen, Hui-Jun ; Liu, Fei ; Zhang, Xiao-Jing ; Fu, Hai-Dong ; Li, Qiu-Yu ; Huang, Ling-Fei ; Lu, Zhi-Hong ; Sheng, Ai-Qin ; Yan, Wei-Li ; Mao, Jian-Hua ; Feng, Chun-Yue

BACKGROUND:

Nephrotic syndrome (NS) is a common form of glomerular disease in children, characterized by a high propensity for relapse. Prolonged use of glucocorticoids (GCs) can result in various side effects. Rituximab (RTX) may be considered as an initial treatment option for primary nephrotic syndrome in pediatric patients.

METHODS:

We conducted a prospective, single-center, randomized controlled trial (RCT) to evaluate whether the initial use of RTX monotherapy is superior to GC therapy in treating pediatric idiopathic NS and to assess its safety. The primary outcome and secondary outcomes were compared between the two groups.

RESULTS:

A total of 24 pediatric patients were included in the study, comprising 19 males and 5 females. After six weeks of treatment, the complete remission (CR) rate in the GC group was significantly higher than that in the RTX group (100% vs 33.3%). Compared with the RTX group, the GC group had a shorter time to first remission (14.25 d vs. 9.5 d). During the follow-up period, none of the patients in the RTX group who achieved CR experienced relapse, with the longest relapse-free duration being 79 weeks. In the GC group, nine patients experienced relapse with the longest relapse-free period being 94 weeks. No serious adverse events occurred in either group. The cumulative steroid dosage was not statistically different between the 2 groups (p = 0.41).

CONCLUSION:

Although the CR rate of children with idiopathic NS treated with RTX alone is significantly lower, the relapse rate among responders to RTX is also lower than that of the GC treatment.

1,982

项与利妥昔单抗相关的新闻（医药）

2025-06-12

·信达生物

ROS1抑制剂己二酸他雷替尼获美国食品药品监督管理局（FDA）批准上市

2025年6月11日，己二酸他雷替尼获美国食品药品监督管理局（FDA）批准用于治疗局部晚期或转移性ROS1阳性非小细胞肺癌（NSCLC）成人患者。2024年12月，己二酸他雷替尼已被中国国家药品监督管理局批准用于ROS1阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。中国大陆地区商品名为达伯乐®，信达生物制药集团负责在大中华区的商业化运营。作为一款高选择性、新一代口服ROS1酪氨酸激酶抑制剂（TKI），己二酸他雷替尼旨在解决当前ROS1阳性NSCLC治疗领域尚未满足的临床需求，展现出高缓解率及持久临床获益，并对颅内病灶显示显著活性，且总体耐受性良好。此次获批为晚期ROS1阳性NSCLC患者提供了重要的全新治疗选择。本次获批是基于FDA的优先审评资格和TRUST临床研究的强力数据支持。己二酸他雷替尼在一线和二线治疗中均展现出高且持续的缓解率，并具有穿透血脑屏障的疗效优势。己二酸他雷替尼在关键临床研究中已充分证实其安全性和良好耐受性，在目前ROS1阳性非小细胞肺癌领域最大规模之一的临床研究安全性数据集中展现出优异且一致的安全性特征。 “晚期ROS1阳性非小细胞肺癌患者及临床医生亟需新的治疗选择，”TRUST研究的研究者、克利夫兰诊所医学教授Nathan Pennell医学博士补充道，“己二酸他雷替尼具有持久的应答持续时间及有效穿透血脑屏障的能力，加之明确且可控的安全性特征，进一步满足了患者的这些关键需求。相信这一现已获批的疗法能为临床医生和患者提供充满前景的晚期ROS1阳性非小细胞肺癌治疗新选择。”Pennell博士是Nuvation Bio顾问委员会受薪成员。此前，于2024年12月，己二酸他雷替尼已被中国国家药品监督管理局（NMPA）批准用于一线及二线治疗ROS1阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。中国大陆地区商品名为达伯乐®，在大中华区由Nuvation Bio的全资子公司葆元医药许可信达生物制药集团负责商业化运营。 FDA批准己二酸他雷替尼的依据是迄今为止ROS1阳性非小细胞肺癌领域全球规模最大的临床试验项目之一，其关键临床研究TRUST-I和TRUST-II在全球共入组了300多名患者。在TRUST-I研究中，己二酸他雷替尼在未接受过TKI治疗的（初治）患者中达到90%的确认客观缓解率（cORR）。这一结果在TRUST-II研究中得到进一步验证，未接受TKI治疗患者的cORR达到85%。截至数据截止日（比2025年4月发表在《临床肿瘤学杂志》上的TRUST-I和TRUST-II汇总分析的数据截止日增加了近五个月），两项试验的中位缓解持续时间（mDOR）均尚未达到。TRUST-I研究的中位疗效随访时间（median follow-up for responses) 为40个月，观察到的最长缓解时间（DOR）已达46. 9个月且仍在持续。TRUST-II研究的中位疗效随访时间为19个月，截至2024年10月观察到的最长缓解时间（DOR）为30. 4个月且仍在持续。由于TRUST临床研究为单臂设计，因此药品说明书中未提供中位无进展生存期（PFS）。在关键性临床研究中，己二酸他雷替尼在既往接受过ROS1 TKI治疗（经治）的患者群体中也展现出持续一致的疗效。TRUST-I研究数据：确认客观缓解率（cORR） 52%，中位缓解持续时间（mDOR）13.2个月，中位随访时间 33个月；TRUST-II研究数据：确认客观缓解率（cORR） 62%，截至2024年10月的中位缓解持续时间 19.4个月，中位随访时间：19个月。脑转移是晚期ROS1阳性非小细胞肺癌最常见且最具破坏性的并发症之一。截至2024年10月针对中枢神经系统（CNS）穿透性进行了特别优化，在基线期存在可测量脑转移灶的患者中展现出持续的颅内疗效：初治患者颅内缓解率为73%（11/15例），经治患者颅内缓解率为63%（15/24例）。己二酸他雷替尼安全性和耐受性良好，大多数不良反应为轻度、一过性且可管理。详见“原文链接” 。关于ROS1阳性非小细胞肺癌- 滑动查看更多介绍 -肺癌是全球发病率和死亡率最高的恶性肿瘤之一，其中NSCLC是最常见的病理类型，全球每年有超过一百万人被诊断患有NSCLC，约占所有肺癌的85%。据估计，约2%的NSCLC患者携带ROS1阳性基因。在初治的转移性 ROS1 阳性NSCLC患者中，高达35%的患者肿瘤已扩散到大脑（即发生脑转移），而对于经第一代ROS1 TKI治疗失败的患者，发生脑转移的比例增加至高达 55%。尽管已有获批ROS1TKI药物，但患者往往在接受治疗后发生疾病进展。关于己二酸他雷替尼- 滑动查看更多介绍 -己二酸他雷替尼是一种口服、强效、中枢神经系统活性、选择性、新一代潜在最佳的ROS1 抑制剂，用于治疗治疗ROS1阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。己二酸他雷替尼在治疗ROS1 阳性非小细胞肺癌患者中的作用在TRUST临床试验项目中得到评估，其中包括两项2期单臂关键临床研究，分别是在中国开展的临床研究TRUST-I(NCT04395677) 和全球关键临床研究TRUST-II (NCT04919811)。此前，于2024年12月，己二酸他雷替尼已被中国国家药品监督管理局（NMPA）批准用于一线及二线治疗ROS1阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者，中国大陆地区商品名为达伯乐®。关于信达生物- 滑动查看更多介绍 -“始于信，达于行”，开发出老百姓用得起的高质量生物药，是信达生物的使命和目标。信达生物成立于2011年，致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，让我们的工作惠及更多的生命。公司已有15个产品获得批准上市，它们分别是信迪利单抗注射液（达伯舒®），贝伐珠单抗注射液（达攸同®），阿达木单抗注射液（苏立信®），利妥昔单抗注射液（达伯华®），佩米替尼片（达伯坦®），奥雷巴替尼片（耐立克®），雷莫西尤单抗注射液（希冉择®），塞普替尼胶囊（睿妥®），伊基奥仑赛注射液（福可苏®），托莱西单抗注射液（信必乐®），氟泽雷塞片（达伯特®），匹妥布替尼片(捷帕力®)，己二酸他雷替尼胶囊（达伯乐®），利厄替尼片（奥壹新®）和替妥尤单抗N01注射液（信必敏®）。目前，同时还有3个品种在NMPA审评中，4个新药分子进入III期或关键性临床研究，另外还有15个新药品种已进入临床研究。公司已与礼来、罗氏、赛诺菲、Incyte和MD Anderson 癌症中心等国际合作方达成30多项战略合作。信达生物在不断自研创新药物、谋求自身发展的同时，秉承经济建设以人民为中心的发展思想。多年来，始终心怀科学善念，坚守“以患者为中心”，心系患者并关注患者家庭，积极履行社会责任。公司陆续发起、参与了多项药品公益援助项目，让越来越多的患者能够得益于生命科学的进步，买得到、用得起高质量的生物药。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。信达生物希望和大家一起努力，提高中国生物制药产业的发展水平，以满足百姓用药可及性和人民对生命健康美好愿望的追求。详情请访问公司网站：www.innoventbio.com或公司领英账号：Innovent Biologics。关于Nuvation Bio和葆元医药- 滑动查看更多介绍 -Nuvation Bio是一家商业化阶段的全球性抗肿瘤生物制药公司，专注于攻克癌症治疗领域重大难题，进而对患者的生活产生深远的积极影响。公司的多样化产品线包括己二酸雷替尼，一种新一代ROS1抑制剂；safusidenib，一种用于胶质瘤的脑渗透性IDH1抑制剂；NUV-1511，一种创新的药物-药物结合物（DDC），旨在针对癌症治疗；以及NUV-868，一种BD2选择性BET抑制剂。葆元医药坐落于浙江省杭州市钱塘区中国医药港，在被Nuvation Bio于2024年4月收购后，成为Nuvation Bio的全资子公司。2021年6月，葆元医药与信达生物签订了独家许可协议，由信达生物在大中华区（包括中国大陆、香港、澳门和台湾）共同开发和商业化己二酸他雷替尼。己二酸他雷替尼胶囊（美国商品名：IBTROZI™；中国大陆地区商品名：达伯乐®；英文通用名：Taletrectinib Adipate Capsules）分别于2024年12月和2025年6月获得中国国家药品监督管理局（NMPA）和美国食品及药品监督管理局（FDA）批准上市，用于一线和二线治疗ROS1阳性的非小细胞肺癌。己二酸他雷替尼之前已于2022年分别获得美国FDA和国家药品监督管理局授予的突破性疗法认证（BTD），用于二线治疗第一代ROS1 TKI已经耐药以及一线治疗未经ROS1 TKI治疗过的晚期或转移性ROS1阳性非小细胞肺癌患者。己二酸他雷替尼也于2024年被FDA授予孤儿药认定（ODD）。作为己二酸他雷替尼全球注册申报的一部分，接下来也将在日本、欧盟等国家和地区陆续递交新药申报。详情请访问公司网站：https://www.nuvationbio.com/声明：1.信达不推荐任何未获批的药品/适应症使用。2.雷莫西尤单抗注射液（希冉择®），塞普替尼胶囊（睿妥®）和匹妥布替尼片（捷帕力®）由礼来公司研发。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，均属于前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务;及 (b) 若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。

优先审批申请上市上市批准临床研究

2025-06-12

·ioncology

2025 ACML丨王三斌&许景艳教授：从突破到精准，免疫治疗前移趋势引领亚太淋巴瘤诊疗新生态

点击蓝字关注我们前言：2025年5月31日至6月1日，由罗氏制药主办的首届亚太地区恶性淋巴瘤会议（APAC congress on malignant lymphoma，ACML）在上海市隆重召开。本次会议聚焦于淋巴瘤领域的前沿进展及热点话题，致力于推动亚太地区在淋巴瘤研究与治疗方面的学术协作与交流，为提升区域淋巴瘤诊疗水平搭建了重要平台。会议期间，中国人民解放军联勤保障部队第920医院王三斌教授、南京鼓楼医院许景艳教授，与基因泰克转化医学部杰出科学家Yanwen Jiang博士及罗氏制药中国血液领域负责人洪晓女士，围绕淋巴瘤诊疗热点议题分享了极具价值的临床洞见。《肿瘤瞭望-血液时讯》特提炼核心内容，以飨读者。挑战尚存疗效天花板亟待打破，特殊人群需求远未满足ACML指南针“提升治愈率、优化治疗耐受性及长期生存获益已成为当下淋巴瘤研究领域的重要方向。”迄今为止，尽管全球淋巴瘤诊疗技术已取得长足进步，但临床实践中的多重桎梏仍制约着患者生存获益的进一步提升。本次ACML会议深度聚焦该领域前沿进展，系统性地提出了治疗策略的革新方向与临床实践的优化路径。会议期间，王三斌教授与许景艳教授通过多维度剖析，揭示了当前治疗格局中亟待突破的两大痛点——疗效“天花板”亟待打破，特殊人群需求远未满足。许景艳教授结合南京鼓楼医院诊疗数据指出：“在原发性中枢神经系统淋巴瘤（PCNSL）患者中，传统甲氨蝶呤为基础的化疗方案五年生存率不尽如人意，且高龄（特别是≥80岁）、肾功能不全等特殊患者，常因药物毒性问题丧失标准治疗机会”。这种治疗可行性与疗效保障的双重缺失，体现了领域治疗范式革新之迫切。王三斌教授进一步强调：“尽管经典R-CHOP方案（利妥昔单抗+环磷酰胺+长春新碱+多柔比星+泼尼松）在淋巴瘤治疗中具有里程碑意义，但临床上仍有众多患者面临难治及复发困境。此外，老年侵袭性淋巴瘤患者常因器官功能储备不足或合并基础疾病，难以耐受标准剂量化疗。针对复发难治性淋巴瘤患者，尤其是中枢神经系统受累者，疗效与生存亟待改善。这些未解难题，共同构成了制约当前淋巴瘤治疗领域整体生存率提升的关键障碍，故而提升治愈率、优化治疗耐受性及长期生存获益已成为当下研究的重要方向”。因此，在分子生物学机制解析不断深入的背景下，凭借精准诊疗技术优化疗效，同时构建覆盖特殊人群的个体化治疗体系，将成为淋巴瘤从"可控制疾病"迈向"可治愈疾病"的核心突破口。破局之策Pola-R-CHP实现生存突破，CD20/CD3双特异性抗体疗效优异ACML指南针“Pola-R-CHP方案显著提升了DLBCL患者的五年无进展生存率，具有持续生存获益优势，为初治患者带来了实质性的疗效改善。”“格菲妥单抗可在透过血脑屏障后，凭借免疫激活功能，有效活化和招募T细胞，发挥精准抗肿瘤效应，有望进一步提升颅内病灶控制率。”“莫妥珠单抗4年长期随访数据显示，滤泡性淋巴瘤患者的ORR接近80%，彰显了其持久、深度缓解的优异疗效。”近年来，众多突破性创新免疫药物的出现为破解领域困局注入了强劲动力。首先，王三斌教授高度评价了抗体药物偶联物（ADC）维泊妥珠单抗（Polatuzumab，Pola）的价值：“作为二十年来首个经全球III期POLARIX研究证实1，疗效优于R-CHOP的创新药物，维泊妥珠单抗实现了弥漫大B细胞淋巴瘤（DLBCL）一线治疗的里程碑式飞跃。”许景艳教授进一步补充了该研究五年随访数据——在DLBCL总体意向性治疗（ITT）人群中，相较于经典R-CHOP方案，Pola-R-CHP方案显著提升了五年无进展生存率（64.2% vs. 59.1%，HR=0.77）2，证实其持续生存获益优势，为初治患者带来了实质性的疗效改善。在复发难治领域及特殊亚型中，双特异性抗体则展现出强大的应用潜力与前景。王三斌教授强调：“侵袭性淋巴瘤领域治疗模式已从传统化疗主导逐步转向靶免治疗协同应用。尽管化疗仍是当前治疗框架的基石，但以格菲妥单抗（Glofitamab）为代表的双抗药物和维泊妥珠单抗已广泛渗透至临床实践，显著改善了患者预后。同时，联合CD20/CD3双特异性抗体的策略正逐步在中枢神经系统淋巴瘤中展现增效潜力。研究显示格菲妥单抗可在透过血脑屏障后，凭借免疫激活功能，有效活化和招募T细胞，发挥精准抗肿瘤效应3，有望进一步提升颅内病灶控制率。”许景艳教授特别指出：“以格菲妥单抗为核心的新型方案，为高龄及不耐受传统化疗的患者提供了全新的治疗希望。未来，临床实践需进一步探索其在联用方案中的最佳模式及精准用药策略，以期实现个体化治疗效益最大化。”同时，针对惰性淋巴瘤领域，许景艳教授分享了CD20/CD3双抗莫妥珠单抗（Mosunetuzumab）GO29781研究的4年长期随访数据——总体滤泡性淋巴瘤患者的客观缓解率（ORR）接近80%4，彰显了其持久、深度缓解的优异疗效。目前，莫妥珠单抗已获批单药用于治疗既往接受过至少两线系统性治疗的复发或难治性滤泡性淋巴瘤成人患者，其高应答率和固定治疗时间模式不仅可能改变领域格局，更为其向一线治疗前移及联合方案探索奠定了循证基础。进无止境格菲妥单抗获批二线，莫妥珠单抗一线研究备受期待ACML指南针“基于格菲妥单抗、莫妥珠单抗等新型免疫治疗药物的卓越疗效，各界正加速推动其适应症‘前移’——从后线走向一/二线治疗。”随着免疫治疗的突破性进展与优质药物的相继出现，淋巴瘤治疗策略趋势逐渐转向免疫治疗线序前移与新型联合方案的系统性探索。许景艳教授清晰阐述了这一演化方向：“基于格菲妥单抗、莫妥珠单抗等新型免疫治疗药物的卓越疗效，各界正加速推动其适应症‘前移’——从后线走向一/二线治疗。”这一趋势在滤泡性淋巴瘤等惰性亚型中尤为显著，特别是莫妥珠单抗的一线研究备受期待；在侵袭性淋巴瘤领域，格菲妥单抗近期凭借明确的生存获益数据，已在国内获批用于复发或难治性弥漫大B细胞淋巴瘤患者的二线治疗，并有望继续向一线治疗适应症拓展。在治疗选择丰富化的背景下，精准风险分层与个体化方案优化同样成为提升临床获益的关键。王三斌教授强调：“未来，突破需聚焦给药方案优化、生物标志物驱动的精准分层及创新联合策略探索。”许景艳教授则在分享中国经验时提及，南京鼓楼医院在胃黏膜相关淋巴组织（MALT）淋巴瘤中，已形成涵盖抗幽门螺杆菌（HP）治疗的标准路径；而对于非胃边缘区淋巴瘤等高肿瘤负荷的惰性淋巴瘤患者，院内正积极探索奥妥珠单抗联合方案等创新策略。针对老年、脆弱及合并脏器功能障碍的患者，“靶免药物的免化疗（chemo-free）方案的开发及与传统疗法的协同应用，正成为提供有效且耐受性更佳疾病控制的重要策略。”综上，免疫治疗线序前移与创新联合方案的探索趋势，有望推动淋巴瘤临床实践向"更有效、更安全、更个体化"的方向持续演进。共赢未来创新免疫药物疗效优势明确，助力优化亚太人群治疗方案ACML指南针“2025 EHA即将公布的POLARIX研究亚组数据，或将为维泊妥珠单抗的广泛应用提供依据，特别是在亚洲人群中可能展现出更显著的生存获益趋势，将为制定符合亚太患者特征的全程管理策略提供重要参照。”“维泊妥珠单抗等创新药物展现的明确疗效优势，可成为构建兼具临床价值与可及性解决方案的突破口。若亚太人群数据进一步验证其治疗优势，将极大推动该药物的标准化应用。"亚太地区淋巴瘤诊疗面临着独特的临床挑战，其人群遗传异质性、疾病谱系特征及医疗资源配置差异，要求构建契合区域特点的解决方案。两位专家在交流中均强调，基于亚洲人群的真实世界数据是优化治疗策略的核心基础。许景艳教授透露，2025欧洲血液学协会年会（EHA）即将公布的POLARIX研究亚组数据，或将为维泊妥珠单抗的广泛应用提供依据，特别是在亚洲人群中可能展现出更显著的生存获益趋势，将为制定符合亚太患者特征的全程管理策略提供重要参照。本次ACML期间汇报的韩国研究数据，亦从多维度验证了该药物的实践价值，凸显其在亚太临床场景中的广泛适用性。王三斌教授从区域协作视角提出战略构想，强调需建立"亚太特色"的诊疗创新生态：“在医疗资源分布不均衡及支付能力存在一定差异的现实背景下，维泊妥珠单抗等创新药物展现的明确疗效优势，可成为构建兼具临床价值与可及性解决方案的突破口。若亚太人群数据进一步验证其治疗优势，将极大推动该药物的标准化应用。"面向淋巴瘤诊疗的未来发展，深化创新药物应用推进个体化方案优化成为关键路径。两位教授一致肯定ACML在促进学术交流与转化研究中的平台价值。许景艳教授期待"依托格菲妥单抗、莫妥珠单抗等新型‘武器’取得的临床突破，开发针对亚太高发亚型及特殊人群的精准治疗路径。"王三斌教授则建议"未来，ACML应定位于前沿成果首发阵地与多中心协作网络枢纽，通过促进跨国药企、临床机构及基础研究团队的深度协同，聚焦未满足临床需求开展联合攻关，最终形成覆盖疾病全周期的精准诊疗体系。"两位专家的期许旨在推动科研成果高效转化为临床实践，为亚太乃至全球患者提供兼具可及性与效价比优势的创新治疗方案，最终实现患者生存预后与生活质量的同步改善。END参考文献：（上下滑动查看更多）1.Gilles Salles, et al; Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes.2.Song Y, Tilly H, Rai S, et al. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial. Blood. 2023 Apr 20;141(16):1971-1981.3.Dickinson MJ, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J]. N Engl J Med, 2022, 387(24): 2220-31.4.Mazyar shadman E A. Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study [J]. 2024ASH, 2024, 4407.（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果免疫疗法临床研究

2025-06-12

·sobi.com

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

Sobi® (STO: SOBI) will present data at the 30th EHA (European Haematology Association) hybrid congress, in Milan, Italy (12-15 June). The congress will feature the latest advances in the treatment of diffuse large B-cell lymphoma (DLBCL), immune thrombocytopenia (ITP), myelofibrosis, paroxysmal nocturnal haemoglobinuria (PNH), and primary hemophagocytic lymphohistiocytosis (pHLH). An extensive programme of poster presentations will showcase Sobi’s commitment to helping patients with rare diseases by advancing treatment options. In addition, Sobi will host several scientific symposiums at the congress including: 1.Advancing Therapeutic Knowledge in Paroxysmal Nocturnal Haemoglobinuria: Reshaping disease management to unlock new norms, Thursday, 12 June, 10:00am - 11:30am CEST, at Amber Hall 3 & 4. 2. Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP), Saturday 14 June, 8.00 am - 9.30 am CEST, at Amber Hall 7 & 8. 3. Dissecting Treatment Sequencing in relapsed/refractory DLBCL, from laboratory to real life. Saturday, 14 June, 8:00 am – 9:30 am, CEST at Coral Hall 1. “The breadth of data that we share at this year’s EHA congress demonstrates Sobi’s comprehensive approach to addressing rare conditions in haematology. We are proud to contribute to advancing the science in several indications from early clinical phases in diffuse large B-cell lymphoma to clinical and real-world evidence in myelofibrosis, primary hemophagocytic lymphohistiocytosis, immune thrombocytopenia and paroxysmal nocturnal haemoglobinuria,” said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. Key data to be presented at EHA 2025 DLBCL PS1911: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large BCell Lymphoma (DLBCL) Presenting Author: Juan Pablo Alderuccio Poster presentation Session title: Poster Session 2Session date: Saturday, 14 June Session time: 18:30-19:30 CEST Location: Poster Hall PS1957: Updated Safety Run-in Results from LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine with Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL Presenting Author: Carmelo Carlo-Stella Immune Thrombocytopenia (ITP) PF1236: Platelet Response to Avatrombopag Among Patients with Primary Immune Thrombocytopenia Who Switched from Eltrombopag or Romiplostim: the REAL-AVA 2.0 Real-World Study Presenting Author: Shruti Chaturvedi Poster presentation Session title: Poster Session 1Session date: Friday, 13 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PF1239: Durability of Response to Avatrombopag Among Patients with Primary Immune Thrombocytopenia: The REAL-AVA 2.0 Real-World Study Presenting Author: Srikanth Nagalla PF1251: Clinically Meaningful Response to Avatrombopag: A Phase 3B Trial for Treatment of Children with ITP Presenting Author: Rachael F. Grace PS2231: Effectiveness and safety of avatrombopag for the treatment of adults with newly diagnosed, persistent, or chronic immune thrombocytopenia: Interim results from the phase 4 ADOPT study Presenting Author: Waleed Ghanima Poster presentation Session title: Poster Session 2Session date: Saturday, 14 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PS2234: Efficacy and safety of avatrombopag for the treatment of pediatric immune thrombocytopenia in the open-label extension of a phase 3, randomized, double-blind, placebo-controlled trial Presenting Author: Rachael F. Grace PS2239: Real-World Treatment Patterns & Clinical Outcomes in Thrombopoietin Receptor Agonist Naive Patients with Immune Thrombocytopenia Treated with Avatrombopag: Interim Results from the REAL-AVA 3.0 Study Presenting Author: Sandhya Panch PS2242: Effectiveness and safety of avatrombopag for treatment of immune thrombocytopenia in older patients and those with comorbidities or prior TPO-RA exposure: Interim results from the phase 4 ADOPT study Presenting Author: María Eva Mingot-Castellano PS2244: Response to Avatrombopag Among Patients with Chronic and Persistent Primary Immune Thrombocytopenia: the REAL-AVA 2.0 Real-World Study Presenting Author: M Y Levy PS2250: Evaluation of Efficacy and Safety of Avatrombopag in Children with Immune Thrombocytopenia based on Disease Duration: Results from the Avatrombopag Phase 3-b Pediatric Trial Presenting Author: Rachael F. Grace PB3676: Baseline Correlates with Durability of Avatrombopag Response: A Phase 3B Trial for Treatment of Children with ITP Publication Only Published on May 14 at 15:30 CEST PB3684: Consistent Response to Avatrombopag across Various Baseline Characteristics: Results from the Phase 3-b Trial for the Treatment of Children with Immune Thrombocytopenia Myelofibrosis PF849: Hematologic improvement experienced by pacritinib-treated patients with myelofibrosis in real-world clinical settings Presenting Author: Michael Marrone Poster presentation Session title: Poster Session 1Session date: Friday, 13 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PF1242: Efficacy of pacritinib vs momelotinib in patients with thrombocytopenic MF: a matched adjusted indicated treatment comparison Presenting Author: Koo Wilson PF1306: Transfusion-related cost and time burden offsets in patients with myelofibrosis treated with pacritinib compared to best available therapy based on PERSIST-2 trial Presenting Author: Abiola Oladapo PS1827: Real-world effectiveness of pacritinib in patients with myelofibrosis who have concurrent thrombocytopenia and anemia Presenting Author: Raajit Rampal Poster presentation Session title: Poster Session 2 Session date: Saturday, 14 June Session time: 18:30-19:30 CEST Location: Poster Hall PS1842: Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x109/L at PAC initiation: Interim results from the MY-PAC Study Presenting Author: Doug Tremblay PS2295: Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database Presenting Author: Lucia Marasova PB3079: Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database Publication Only Published on May 14 at 15:30 CEST Paroxysmal Nocturnal Hemoglobinuria PF672: Early response in complement inhibitor naïve patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan in the Phase 3 PRINCE trial Presenting Author: Austin Kulasekararaj Poster presentation Session title: Poster Session 1Session date: Friday, 13 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PF676: Interim analysis of the ongoing COMPLETE study on the real-world effectiveness of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH) Presenting Author: Regis Peffault de Latour PS1662: A benefit assessment of pegcetacoplan dose increase in the Phase 3 PEGASUS trial of PNH patients with difficult-to-control disease Presenting Author: Morag Griffin Poster presentation Session title: Poster Session 2Session date: Saturday, 14 June Session time: 18:30 - 19:30 CEST Location: Poster Hall PS1665: Benefit of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria irrespective of baseline transfusion status Presenting Author: Britta Höchsmann Primary Hemophagocytic Lymphohistiocytosis (pHLH) PF1036: Emapalumab in patients with primary hemophagocytic lymphohistiocytosis: Efficacy and safety outcomes from a multinational, open-label, single-arm study Presenting Author: Franco Locatelli Poster presentation Session title: Poster Session 1Session date: Friday, 13 June Session time: 18:30 - 19:30 CEST Location: Poster Hall About pegcetacoplan in rare diseases Pegcetacoplan is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, a part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is under investigation for rare diseases across haematology and nephrology. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as EMPAVELI®/Aspaveli® in the United States, European Union, and other countries globally About Doptelet® (avatrombopag) Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. About Zynlonta® (loncastuximab tesirine)Zynlonta® (loncastuximab tesirine) is a CD19-directed antibody drug conjugate (ADC). Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. About Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. We provide access to innovative treatments that transform life for people. Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care. We contribute to societies by improving access to treatment of rare diseases. Every day, we work actively to find better ways to understand and meet patient needs. Find out more about our business and financial performance. Here we present current and past media releases, images and videos.

临床3期免疫疗法临床结果上市批准临床1期

100 项与利妥昔单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02994	利妥昔单抗	L01XC02	DB00073

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心脏移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肝移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肺移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
胰腺移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
肾移植排斥反应	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
小肠移植排斥	日本	Zenyaku Kogyo Co., Ltd.	2023-12-22
狼疮性肾炎	日本	Zenyaku Kogyo Co., Ltd.	2023-08-23
视神经脊髓炎	日本	Zenyaku Kogyo Co., Ltd.	2022-06-20
巴西天疱疮	日本	Zenyaku Kogyo Co., Ltd.	2021-12-24
家族性寻常型天疱疮	日本	Zenyaku Kogyo Co., Ltd.	2021-12-24
获得性血栓性血小板减少性紫癜	日本	Zenyaku Kogyo Co., Ltd.	2020-02-21
CD20阳性B细胞慢性淋巴细胞白血病	日本	Zenyaku Kogyo Co., Ltd.	2019-03-26
淋巴细胞白血病	日本	IDEC Pharmaceuticals Corp.	2019-03-26
淋巴细胞白血病	日本	Genentech, Inc.	2019-03-26
慢性特发性血小板减少性紫癜	日本	Zenyaku Kogyo Co., Ltd.	2017-06-26
血小板减少性紫癜	日本	IDEC Pharmaceuticals Corp.	2017-06-26
血小板减少性紫癜	日本	Genentech, Inc.	2017-06-26
肾病综合征	日本	Genentech, Inc.	2014-08-29
肾病综合征	日本	Zenyaku Kogyo Co., Ltd.	2014-08-29
肾病综合征	日本	IDEC Pharmaceuticals Corp.	2014-08-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性 3a 级滤泡性淋巴瘤	临床3期	美国	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	中国	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	日本	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	澳大利亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	比利时	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	保加利亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	加拿大	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	克罗地亚	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	捷克	Genmab A/S	2024-02-05
难治性 3a 级滤泡性淋巴瘤	临床3期	丹麦	Genmab A/S	2024-02-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03863184 (CTgov)	临床2期	套细胞淋巴瘤	37	Lenalidomide+Acalabrutinib+Rituximab (ALR in Combination)	壓窪醖齋夢構簾憲衊壓 = 廠憲齋遞願鏇遞艱繭鏇壓廠淵襯鑰憲簾獵壓壓 (網顧艱繭製壓艱餘窪廠, 窪製構網襯鏇構顧廠膚 ~ 鹽觸糧網顧顧範鹹醖顧)	-	2025-06-06
				Lenalidomide+Acalabrutinib+Obinutuzumab (ALO in Combination)	壓窪醖齋夢構簾憲衊壓 = 鬱齋窪鑰醖廠鬱衊膚衊壓廠淵襯鑰憲簾獵壓壓 (網顧艱繭製壓艱餘窪廠, 鏇衊廠鹹遞簾範範糧鬱 ~ 蓋選選鑰淵顧餘窪鹹築)
NCT02356159 (CTgov)	临床1/2期	霍奇金淋巴瘤 \| 多发性骨髓瘤 \| 急性白血病 ... 更多	34	Epinephrine+PET+Acetaminophen+prednisone+EPOCH-F+Palifermin+Diphenhydramine+Rituximab (2/Phase II Arm - Palifermin at the Recommended Phase 2 Dose)	鹽壓齋衊繭築夢願夢壓 = 選獵鏇選鏇遞築觸鬱廠餘製襯鹽廠齋鹽獵憲鹽 (齋鹹鏇願餘齋鬱廠襯夢, 壓壓夢衊糧窪醖餘淵觸 ~ 築鬱鬱顧獵製願糧壓範)	-	2025-06-05
				Epinephrine+PET+Acetaminophen+prednisone+EPOCH-F+Palifermin+Diphenhydramine+Rituximab (1/Phase 1: Dose Escalation Arm - Palifermin)	鬱壓觸鑰構憲構淵醖憲 = 獵觸網繭鑰鏇鹽糧遞醖築選餘鏇鹹築簾積窪構 (構糧廠醖鹹積憲製範觸, 糧窪鹹糧壓獵壓艱壓艱 ~ 夢構齋壓築餘構構蓋壓)
ATS2025	N/A	心脏结节病	-	Rituximab	範鏇鑰願憲顧觸夢憲網(淵遞壓鬱壓淵醖廠積網) = 壓衊範膚構醖廠築糧獵廠襯鹹糧餘鹽簾艱遞淵 (糧齋糧憲艱蓋網觸餘鬱 ) 更多	-	2025-05-16
				Corticosteroids and Immunosuppressive Therapies	範鏇鑰願憲顧觸夢憲網(淵遞壓鬱壓淵醖廠積網) = 壓網遞廠獵選選獵簾鑰廠襯鹹糧餘鹽簾艱遞淵 (糧齋糧憲艱蓋網觸餘鬱 )
ATS2025	N/A	结缔组织病相关间质性肺疾病	5	Rituximab	鏇廠構觸築遞繭鹹簾鬱(鹹構廠願積願鏇窪襯範): RR = 0.57 (95% CI, 0.26 ~ 1.26), P-Value = 0.17 更多	积极	2025-05-16
				Placebo/Standard Treatment
ATS2025	N/A	结缔组织病相关间质性肺疾病	113	Rituximab	網鏇壓衊鑰夢餘鑰淵築(鏇範鑰觸淵廠選製廠壓) = 糧糧鬱憲憲夢淵構選淵鬱膚製製選膚壓鹽膚餘 (襯選範築蓋窪蓋膚鏇網, +45) 更多	积极	2025-05-16
NCT04673617 (ASGCT2025)	临床1/2期	难治性非霍奇金淋巴瘤 CD20 positive	-	Rituximab (AlloNK)	繭顧選襯鏇築顧夢糧衊(衊製襯襯壓簾衊願艱壓) = 4 patients (9%; 3 Grade 1 cases and 1 Grade 2 case) 廠廠築醖網醖廠膚糧鹹 (鏇襯憲醖遞顧鹽網願繭 ) 更多	积极	2025-05-13
				AlloNK + Rituximab
NCT03719131 (CTgov)	临床2期	皮肤黑色素瘤 \| 转移性黑色素瘤 \| 不可切除的黑色素瘤	15	Ipilimumab+Nivolumab (Arm A (Standard of Care))	範選獵觸積網獵憲積壓 = 鹽憲鹽繭糧獵窪積齋廠製選願構膚糧願鏇窪繭 (艱鑰廠築繭鹹鑰鹽憲選, 憲蓋醖網選顧餘窪壓遞 ~ 願鏇醖繭淵構鹽襯壓夢) 更多	-	2025-04-22
				Ipilimumab+Nivolumab+Hyaluronidase+Rituximab (Arm B (Rituximab, Hyaluronidase Human))	範選獵觸積網獵憲積壓 = 襯構壓築範鑰網醖鑰積製選願構膚糧願鏇窪繭 (艱鑰廠築繭鹹鑰鹽憲選, 鏇鑰願簾遞鹹餘廠壓壓 ~ 積鏇觸願襯糧淵鑰蓋網) 更多
P10-1.004 (AAN2025)	N/A	多发性硬化症 anti-CD20-antibodies	192	Anti-CD20-antibodies	願糧憲壓衊蓋獵築醖網(糧選鏇夢廠築製鹽鹹範) = 膚鹹齋願構顧網夢糧願襯繭鏇醖壓鑰簾廠獵獵 (鹽餘鏇獵糧艱獵構遞齋 )	积极	2025-04-07
NCT03615105 (CTgov)	临床2期	霍奇金淋巴瘤 \| Ph样急性淋巴细胞白血病 \| 急性髓性白血病 ... 更多	9	Hyperfractionated total body irradiation+Cyclophosphamide+Rituximab+Thiotepa (Radiation, Thiotepa & Cyclophosphamide)	壓淵繭遞餘鑰齋簾齋網 = 窪選憲憲窪構蓋繭範壓顧淵觸築餘醖蓋築築窪 (顧構餘鬱衊壓衊憲構淵, 蓋糧積觸淵遞膚壓構鏇 ~ 憲窪廠膚夢繭餘廠襯鹹) 更多	-	2025-04-06
				HPC(A) stem cell allograft+Fludarabine+Busulfan+Melphalan+Rituximab (Busulfan, Fludarabine & Melphalan)	壓淵繭遞餘鑰齋簾齋網 = 遞範糧鹹鏇製襯蓋構膚顧淵觸築餘醖蓋築築窪 (顧構餘鬱衊壓衊憲構淵, 襯築選範積餘範衊製簾 ~ 鬱鬱淵製醖構積廠積繭) 更多
NCT02378298 (CTgov)	临床4期	格雷夫斯眼病	38	RTX+MTX (Non-responders RTX+MTX (NR-RTX))	構積範糧齋範觸觸願鏇(遞艱壓膚鏇鑰糧醖淵廠) = 築餘廠窪淵顧積襯顧淵憲壓顧簾鑰衊餘廠齋構 (鏇廠鹽艱餘衊壓顧繭餘, 0.99) 更多	-	2025-03-26
				Methylprednisolone+RTX+MTX (Responders (R-CG))	構積範糧齋範觸觸願鏇(遞艱壓膚鏇鑰糧醖淵廠) = 鑰鏇膚窪餘鹽範鬱願憲憲壓顧簾鑰衊餘廠齋構 (鏇廠鹽艱餘衊壓顧繭餘, 1.36) 更多